• Hematology Calculations 1.2 Purchase For Mac

Bethany Samuelson, MD Published on: March 01, 2014 Kimmel SE, French B, Kasner SE, et al. N Engl J Med. Verhoef TI, Ragia G, de Boer A, et al. N Engl J Med. Pirmohamed M, Burnside G, Eriksson N, et al.

N Engl J Med. For decades, vitamin K antagonists (VKAs) such as warfarin have been the standard oral anticoagulant used to prevent or treat thromboembolic disease. Although the VKAs are effective, their narrow therapeutic window, combined with the significant inter-individual variability in dose response, makes this class of medications challenging to use. Once the decision has been made to initiate treatment with a VKA, the therapeutic focus is on maximizing the percentage of time in the therapeutic range (TTR), as a higher percentage of TTR correlates with better clinical outcomes. 1, 2 In the last 10 years, scientists have identified common genetic polymorphisms that impact the pharmacodynamic effect of VKAs. Specifically, testing for single-nucleotide polymorphisms in the genes VKORC1 (Vitamin K epoxide reductase complex subunit 1) and/or CYP2C9 (cytochrome P450 2C9) improves the accuracy of warfarin dose prediction, raising the hope that genotype-guided dosing might increase the safety and efficacy of coumarin therapy.

Until now, however, sufficiently powered clinical studies designed to test whether genotype-guided dosing improves TTR or clinical outcomes have been lacking. Randomized Controlled Trials of Pharmacogenetic Testing Number of Patients Follow-Up (weeks) Clinical Factors Used to Estimate Dose for Control Group TTR (%) PG Control P value Kimmel, et al. 1015 4 Yes 45.2 45.4 0.91 Verhoef, et al. 548 12 Yes 61.6 60.2 0.52 Pirmohamed, et al. 455 12 No.

67.4 60.3 75 years old who received 5 mg daily on days 1-3. Recently, Stephen E. Kimmel et al. Of the COAG group and Talitha I. Verhoef et al.

Of the EU-PACT group compared dosing algorithms based on both clinical and genotypic variables with algorithms based solely on clinical variables. Patients in the COAG trial had INRs checked twice a week for two weeks, then weekly for two weeks. Patients in the EU-PACT trial had a similar evaluation timeline with the addition of INR checks at eight and 12 weeks. Neither study found a significant difference between genotype-guided and control dosing groups for the primary endpoint of TTR during warfarin initiation (Table).

Munir Pirmohamed et al. Used a slightly different trial design, comparing a dosing algorithm based on genotype and clinical variables with a three-day standardized loading dose regimen in which all control-group patients received an identical dose for the first three days (except those older than 75 years who received a smaller dose on day 1).

Hematology Calculations 1.2 Purchase For Mac

In this trial, the genotype-guided group had a modestly greater TTR (67.4% vs.